Last Updated : May 2, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Cosentyx | secukinumab | Hidradenitis suppurativa | Suspended | |||
| Leqembi | lecanemab | Alzheimer’s disease | Pending | |||
| Ferinject | ferric carboxymaltose | Iron deficiency anemia | Pending | |||
| Epidiolex | cannabidiol | Seizures associated with Tuberous Sclerosis Complex (TSC) | Active | |||
| Epidiolex | cannabidiol | Dravet Syndrome (DS) | Active | |||
| Epidiolex | cannabidiol | Lennox-Gastaut Syndrome (LGS) | Active | |||
| Vraylar | cariprazine | Schizophrenia | Active | |||
| Adcetris | Brentuximab vedotin | Hodgkin lymphoma | Received | |||
| Hemgenix | etranacogene dezaparvovec | Hemophilia B | Active | |||
| TBC | danicopan | Paroxysmal nocturnal hemoglobinuria (PNH) | Active |
Last Updated : May 2, 2024